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570 patients with acute ankle joint distortion were randomized to four treatment groups: a combination spray of arnica tincture
and hydroxyethyl salicylate (HES; group A, n = 228), arnica (B, n = 57), HES (C, n = 228), and placebo (D, n = 57). The
medication was applied 4-5 times daily for 10 days. Eﬃcacy was assessed on day 3-4 by evaluating pain on motion on a visual
analogue scale (VAS). Pain improvement in group A was signiﬁcantly superior over groups B–D (t-test with unadjusted baseline
values, P<4 × 10
−7 and ANCOVA after adjustment, P<5 × 10
−11) and approximately corresponded to the cumulative eﬀect of
the single constituents (12.1, 7.5, and 18.7mm VAS for A versus B, A versus C, and A versus D; 95% CI 8.0–16.2, 4.7–10.4, and
14.8–22.5mm). The combination is justiﬁed by the additive eﬀects of the single active constituents.
1.Introduction
A combination product with arnica tincture (aqueous-
ethanolic extract from the ﬂowers of Arnica montana)a n d
hydroxyethyl salicylate (HES) as active constituents in the
galenical formulation of a spray registered as a medicinal
product has a long history of clinical use in ankle joint
distortion in Germany and the Czech Republic, although
there is little published clinical evidence from trials [1].
Topical anti-inﬂammatory and analgesic properties of
preparations from arnica ﬂowers are amply described in
monographs [2–4]. Flavonoids and sesquiterpene lactones
of the helenalin type are generally held responsible for
the observed eﬀects [5]. HES possesses local analgesic and
anti-inﬂammatory eﬀects, which have been conﬁrmed in
various pharmacological models [6–9], as well as in a clinical
trial [10].
The local analgesic eﬀects of the combination spray
with arnica tincture and HES have been shown eﬃcacious
in a pharmacodynamic proof of concept trial in healthy
volunteers using transcutaneous electric nerve stimulation
for the assessment of pain threshold [11]. The study results
indicated a superiority of the combination over the two
single constituents. The present study has a similar design
but is performed as a conﬁrmatory clinical trial in patients.
It had a twofold aim: to demonstrate the eﬃcacy and
tolerability of the combination spray against ankle joint
distortionunderrandomizeddouble-blindconditionsversus
placebo and to provide details on the contribution to eﬃcacy
of the single constituents. It was hypothesized that the eﬀect
of the combination is superior over the eﬀect of HES or that
of arnica tincture when applied as a monopreparation.
2.MaterialsandMethods
2.1.TrialDesign. Theclinicaltrialwasdesignedasaprospec-
tive, randomized, reference-controlled, double-blind, and
four-arm parallel group phase IV study, performed in two
study centres. No changes were made after commencing the
trialwithrespecttoeligibilitycriteriaoranyotherparameter.2 Pain Research and Treatment
2.2. Ethical Aspects. The conduct of the trial was planned
and carried out in accordance with the criteria of Good
Clinical Practice (GCP) and the International Conference
on Harmonisation (ICH) and the ethical standards deﬁned
in the declaration of Helsinki and described by Harriss
and Atkinson (2009) [12]. The trial was registered under
EudraCT no. 2004-004972-35.
All patients (or, in the case of children, their legal
representatives) signed an informed consent form. The trial
design and the inclusion of children were approved by the
local Institutional Reviewing Board (Ethics Committee) and
the Czech State Institute for Drug Control (SUKL).
2.3. Participants. 570 patients with acute ankle joint distor-
tion were screened and included into the study (ITT popula-
tion). Patients with acute unilateral trauma of the ankle joint
(lateral ankle distortion) had to present themselves within
24 hours after injury. The condition had to be suﬃciently
painful to require therapy. The use of anti-inﬂammatory
or analgesic drugs, corticosteroids, and antidepressants was
not permitted before and during the study, as was any kind
of local treatment including physiotherapy or cold packs.
Patients with fractures or complete tears of ligaments were
excluded. Sports professionals and pregnant women were
likewise excluded. There was no speciﬁc inclusion criterion
deﬁned regarding the severity of pain, and no stratiﬁcation
by severity was made.
2.4. Interventions. All four study preparations were based
on the identically composed solution of excipients in 78%
ethanol (v/v) in the presentation as a cutaneous spray (con-
trolgroupD).Thefourstudypreparationswereproducedby
the same contract manufacturer (Gehrlicher Pharmazeutis-
che Extrakte GmbH, D-82547 Eurasburg, Germany) using
the same validated manufacturing method for all four med-
ications. The basic preparation contained essential oils and
camphor,whichensuredthatthediﬀerentstudypreparations
were not discernible by their organoleptic properties. The
active medications of groups A (combination), B, and C
(single substance) diﬀered from the control preparation in
group D only by the addition of arnica tincture (10g/100mL
solution, groups A and B) and/or hydroxyethyl salicylate
( H E S ;3g / 1 0 0m L ,g r o u p sAa n dC ) .
The combination preparation of group A corresponded
to the medicinally authorized commercial preparations
Arnidol and Sportino (study sponsor: Harras Pharma Cura-
rina GmbH, D-81373 Munich). One stroke of the spraying
device delivers 100μl of the solution. The standard dose was
ﬁve strokes (500μl), delivering approximately 41.5mg arnica
tincture (groups A and B) and 12.5mg HES (groups A and
C). The intervention was applied for 10 ±2d a y s .
2.5. Outcome Parameters. The primary outcome parameter
was pain on active motion, assessed on day 3-4. Follow-up to
day 10 ± 2 served for the evaluation of safety of application
over the total healing time. Pain was assessed on a 100mm
nongraded visual analogue scale (VAS) directly after quickly
walking a distance of approximately 10m.
Table 1: Demographic data.
Gender
Male 358 (62.8%)
Female 212 (37.2%)
Age 30.8 ±10.9 years (Mean ±SD)
Range 6–75 years
6–12 years 10 (1.8%)
13–17 years 36 (6.3%)
18–30 years 253 (44.4%)
31–50 years 250 (43.9%)
≥51 years 21 (3.7%)
Origin of injury
Sports accident 63.2%
Household 18.9%
Work 11.6%
Traﬃc 6.0%
Other 0.4%
Time between injury
and consultation
Mean ±SD 10.1 ±6.8h o u r s
Median 8h o u r s
Range 1–24 hours
As a secondary outcome measure, ankle swelling was
measured using the ﬁgure-of-eight method [13]. The length
of tape was documented in mm. Further secondary parame-
ters included the assessment of the overall treatment eﬀect
by the physician on a ﬁve-step verbal rating scale (VRS;
1 = very good eﬀect; 2 = good; 3 = moderate; 4 =
minor; 5 = no eﬀect). For the assessment of tolerability,
speciﬁc attention was given to all reports of burning and
itching sensations, reddening or scaling of the skin, and
urticaria or folliculitis. Other events could be described. The
correspondingsymptomswereratedonafour-stepVRS(0 =
normal; 1 = slight; 2 = moderate; 3 = severe reaction).
Moderate and severe reactions qualiﬁed as adverse events.
N oc h a n g e sw e r em a d et ot h ep r e d e ﬁ n e do u t c o m e
measures during the study.
2.6. Sample Size. A sample size calculation was made based
on observations from a clinical pharmacology study [11],
wheretheincreaseofpainthresholdwasmeasuredseparately
for the combination and its single constituents versus active-
substance-freecontrolbyusingtranscutaneouselectricnerve
stimulation (TENS). Based on our experience with the simi-
lar eﬃcacy of a comfrey cream preparation in the treatment
of ankle joint distortion [14], we assumed a standardized
diﬀerence for the arnica/HES-combination versus control
of 0.75. In the TENS study, HES was approximately 1.5
times more eﬀective than arnica tincture. Furthermore, we
assumed individual standardized diﬀerences between test
group and control of 0.3 and 0.45 for arnica tincture and
HES, respectively. Sample sizes for the four treatment groups
were calculated based on a t- t e s tw i t ha nα-error of 0.05 andPain Research and Treatment 3
Table 2: Unadjusted and adjusted intergroup diﬀerences for pain on motion versus baseline at day 3-4. A = combination; B = arnica; C =
HES; D = control.
Group comparison Relative diﬀerence (mm VAS) 95% CI P-value∗
Unadjusted baseline values (conﬁrmatory analysis at day 3-4, ITT)
A versus B 12.1 8.0–16.2 5.6 ×10
−8
A versus C 7.5 4.7–10.4 3.3 ×10
−7
A versus D 18.7 14.8–22.5 3.0 ×10
−16
Adjusted baseline values (descriptive analysis at day 3-4, ITT)
A versus B 15.2 10.9–19.4 1.4 ×10
−11
A versus C 9.7 6.9–12.6 4.8 ×10
−11
A versus D 24.8 20.4–29.1 3.9 ×10
−24
∗2-tailed t-test for equality of means for unadjusted values, ANCOVA for adjusted values.
Table 3: Treatment responders (ITT-population). Statistical comparisons (χ2 -test) reﬂect comparisons of group A with the other test
groups.
Group Responder (n)% P
A (Combination) 199/228 87.3 —
B (Arnica) 32/57 56.1 8.1 ×10
−8
C (HES) 168/228 73.7 2.5 ×10
−4
D (Control) 27/57 47.4 2.9 ×10
−11
a power for every single test between 0.85 and 0.9, resulting
in a total of 575 patients (n = 230 in groups A and C each;
n = 65 in group B; n = 50 in control group D). Final sample
sizesdeviatedtoaminorextentfromthiscalculationtoallow
randomisation in blocks.
2.7. Randomisation and Blinding. The study preparations
were manufactured and labelled according to a computer-
generated random list provided by the contract manufac-
turer of the study medication. Concealment was ensured
by fully blinding the investigators, study centres, and the
statistician to the random sequence of patient allocation.
Upon inclusion, eligible patients were double-blindly
allocated by the investigators to the next available position
of the randomization list in the sequence of their entry into
the study, which resulted in a patient distribution ratio of
4:1:4:1(groupA:n = 228; group B: n = 57; group C:
n = 228; group D: n = 57).
2.8.StatisticalMethods. SPSSv.16.0wasusedasthestatistical
software. All conﬁrmatory analyses were made in the ITT
population (all patients returning for the ﬁrst visit on day
3/4). The mean decrease of pain on active motion was
calculated in each group and submitted to statistical testing
in the sequence of group A versus B, A versus C, and A versus
D(nullhypothesis:nodiﬀerencebetweengroups).Following
the closed-test principle, every pair of hypotheses was tested
at a two-sided signiﬁcance level of 0.05, which maintains
the overall signiﬁcance level at 0.05. Due to considerable
baseline diﬀerences in pain on motion between groups,
an additional analysis of covariance (ANCOVA) adjusting
for equal baseline values was performed as a descriptive
parameter.
Descriptive secondary analyses including tolerability
were performed in the per-protocol population at the ﬁnal
visit, using parametric and nonparametric statistical tests.
Finally,thenumberneededtotreat(NNT)wascalculatedfor
the comparison of group A versus D. Treatment responders
weredeﬁnedaspatientsexperiencinganimprovementversus
baseline of at least 16mm on the VAS in pain on active
motion on day 3-4.
3. Results
3.1.Recruitment. Theﬁrstpatientwasincludedon31August
2005, and the ﬁnal visit of the last participant took place on
17 May 2008. A ﬂowchart of patient distribution throughout
t h et r i a li sg i v e ni nFigure 1.
570 outpatients were included and available for the ITT
analysis at day 3-4. Four patients discontinued participation
after the conﬁrmatory visit (day 3-4). The inclusion and
exclusion criteria were met in all cases. The demographic
data are presented in Table 1.
3.2. Primary Eﬃcacy Parameter: Pain on Active Motion.
Pain was not equally distributed at baseline: signiﬁcant
diﬀerences in pain on motion were found among groups
(ANOVA, P<. 0005). Baseline pain on active motion was
lowest in the combination group A (mean = 62.31 ±
19.1mm VAS, Figure 2). The highest baseline values were
found in the control group D (mean = 80.32 ± 17.3).
These baseline diﬀerences had to be taken into account in
the statistical analysis. Correspondingly, the conﬁrmatory
analysis calculated with the unadjusted data (as planned in
the study protocol) was compared with an analysis made
with the ﬁgures adjusted for equal baseline values (Table 2).4 Pain Research and Treatment
n = 227
Completed
day10 ±2
n = 57
Completed
day10 ±2
n = 226
Completed
day10 ±2
n = 56
Completed
day10 ±2
n = 1
Terminated
after day 3-4
(urticaria,
local irritation)
n = 0
No early
terminations
n = 2
Terminated
after day 3-4
(urticaria,
reddening,
urticaria,
allergic
reaction)
n = 1
Terminated
after day 3-4
(urticaria,
lack of
compliance)
n = 228
Group A
n = 57
Group B
n = 228
Group C
n = 57
Control
n = 570
Patients
randomised
3pt
Figure 1: Flowchart of patient distribution to treatment groups.
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Figure 4: Global assessment of eﬃcacy by the physicians at day 3-4 (visit 1, Figure 4(a)) and day 10 (visit 2, Figure 4(b)).
As expected, pain on active motion decreased over the
study period in all groups (unadjusted values, Figure 2).
The best results for pain reduction were found with
the combination. The outcome was not diﬀerent when the
calculation was made with adjusted values (Table 2).
The diﬀerences among groups were likewise statistically
signiﬁcant in the responder analysis (patients experiencing
an improvement versus baseline of at least 16mm on the
VAS in pain on active motion on day 3-4, Table 3). The
number needed to treat (NNT) was 2.5 for the combination
product.
Subgroup analyses for time span between accident and
presentation, origin of injury, gender, or age did not
show relevant or statistically signiﬁcant diﬀerences when
compared with the overall outcome. The subgroup analyses
generally conﬁrmed the sequence of eﬀects A > C > B > D
(data not shown).
3.3. Secondary Parameter: Ankle Swelling. Ankle swelling
decreased in all groups over time (Figure 3). The mean
decrease from baseline to the conﬁrmatory visit at day
3-4 was numerically larger in the combination group A6 Pain Research and Treatment
(8.1mm versus baseline, compared to 5.6–7.1mm in the
other groups). Healing was also quickest in group A: at day
3-4, the reduction of swelling corresponded to 57% of the
overall eﬀect at day 10±2, compared to 37–41% in the other
groups). The superiority of the combination versus group B
was nominally signiﬁcant (P = .047; 2-tailed t-test), but not
versus the other groups (A versus C: P = .074; A versus D:
P = .5). The study was, however, not powered to conﬁrm
diﬀerences between groups with this endpoint.
3.4. Global Assessment of Eﬃcacy by the Physician. On the
conﬁrmatory visit at day 3-4, the global eﬃcacy of the
combination was judged to be good or very good in 77%
of patients, compared to 30% in group B, 44% in group C,
and 25% in the control group D. At the end of the study,
these values further improved to 85% good to very good
assessments in group A, 46% in group B, 58% in group
C, and slightly decreased to 23% in group D (Figure 4).
Statistical signiﬁcance in favour of the combination was
found in all group comparisons (P ≤ 9.1 × 10
−11; Mann-
Whitney test).
3.5. Safety of Application. Local intolerability reactions
(burning, reddening, itching, urticaria) were observed in
4/228 patients of group A (1.75%), in 2/228 patients of
group C (0.88%), and in 3/57 patients of the control group
D (5.26%). No such reactions were observed in group B
(n = 57). In the four cases, the local intolerability reaction
led to discontinuation (Figure 1). There was no signiﬁcant
diﬀerence in incidence rate and symptom severity between
the combination group and the comparative groups.
4. Discussion
The group diﬀerences for pain on active motion on the VAS
(a method applied in accordance with a guidance supplied
by the German drug regulatory authority [15]) conﬁrm
approximately additive eﬀects of the two single constituents,
and thus provide a justiﬁcation for the clinical application
of the combination. As already observed in the model study
withtranscutaneouselectricnervestimulation[11],HESwas
approximately 1.5 times more eﬀective than arnica tincture.
In addition, the results for pain reduction and for the NNT
must be considered clinically important. Changes in pain
assessment as small as 6–8mm on a 100mm VAS are clearly
noticeable for patients and thus clinically important [16–
19]. This precondition was met for groups A–C. For the
NNT, values < 4 are considered clinically important in
pain reduction [20]. The calculated NNT of 2.5 for the
combination is in the magnitude of the NNT found with the
application of oral NSAID [21].
Local tolerability of the combination and the single
constituents was better than the tolerability of placebo. The
frequency of such reactions of 5% in the control group is in
therangeofexpectationsfortopicaldrugsandspeciﬁcallyfor
ethanol-basedsolutions,asconcentratedethanolmayirritate
sensitive skin. The frequency of intolerability reactions in the
Arnica and the HES groups of 1-2% is usually considered
acceptable.Theobservationofalowerincidencerateofintol-
erability reactions in the combination group as compared
to control might be related to the anti-inﬂammatory eﬀects
of the active substances which potentially contribute to the
prevention of such adverse eﬀects.
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